Contact Us
Search
Close this search box.

Biopharmaceuticals

Related topics:

The development of biopharmaceutical products is a challenging and costly process. Our scientists have supported numerous development studies and can be valuable assets where expertise and consultation in analytical method development are concerned. Please follow the link for more information.

Within biosimilarity studies attention is on the collection of evidence that proves that no differences larger than method variability exist in the structure and purity of a proposed biosimilar and the reference product. Supporting data is collected through extensive analytical testing that sets the focus differently than for product development. A customized study design is required for each respective task. Please follow the link for more information.

Peptides comprise a family of molecules that include fragments of proteins, hormones, toxins, antimicrobials, and many more. Their therapeutic value is high, but analytical handling of peptides is challenging, and instrumentation is run at its physical limits.  Expertise and extensive experience in working with small species such as peptide-based APIs is imperative for successful method development. Please follow the link for more information.

For gene therapy product development, traditional quality attributes like product purity are just as important as aspects such as the ratio of particles that carry nucleic acids to empty particles. Approaches for gene therapy API analysis are therefore diverse. Our scientists will help you with the challenging task of product characterization. We have worked with a wide range of different gene therapy products, ranging from small DNA / RNA complexes over lyposome-based carrier systems and adeno-associated viruses (AAV) to viruses that are several hundred nanometers in size and will assist you with your product. Please follow the link for more information.

ZentriForce Pharma offers a wide range of analytical techniques. Please follow the link to our analytical portfolio. 


General topics:

ZentriForce Pharma was founded as a service provider that specializes in hydrodynamic techniques for biopharmaceutical development. The focus lies on gene therapy products and biosimilarity studies. Follow the link to our company page for further information.

Please follow this link to our contact page

ZentriForce Pharma implemented a strict quality system to assure the highest tractability of results generated at our facility. We have a wide range of quality related standard operation procedures (SOPS) in place to assure the consistency and quality of our laboratory operations. Please follow the link to a description of our quality system. 

ZentriForce Pharma is your expert in analytical services, with focus on hydrodynamic techniques. Please follow the link to find out about our analytical services. 

ZentriForce Pharma offers a wide range of analytical techniques. Please follow the link to our analytical portfolio. 

ZentriForce Pharma is not merely an expert in analytical development. Our scientist are actively involved in further advances in the theory of hydrodynamic techniques. Follow the link to a detailed description of the theory behind our analytical services, including some of our own research

ZentriForce Pharma is always looking for motivated employees. Check out our career page for further information. 

Biopharmaceuticals

Within this section we focus on protein / peptide-based products. Gene therapy products, though biopharmaceuticals per definition, are discussed in the Gene Therapy section.

Protein (especially antibody) based products comprise the largest group of biopharmaceuticals.  Despite increased interest in gene therapy products, antibody-based drugs will dominate the pharmaceutical industry for a long time.

Biopharmaceutical studies can be sorted into the following subsections:

Biopharmaceutical Development

The development of biopharmaceutical products is a challenging and costly process. Our scientists have supported numerous development studies and can be valuable assets where expertise and consultation in analytical method development are concerned. For biopharmaceutical development we focus on the support of production optimization, the development of analytical methods and assistance in formulation development., Please proceed to our biopharmaceutical development page for further information.

Biosimilarity Studies

Within the next couple of years, a large number of important patents will expire. To successfully establish a competitor in the market, you must prove your product’s biosimilarity to the originator.  

Within biosimilarity studies attention is on the collection of evidence that proves that no differences larger than method variability exist in the structure and purity of a proposed biosimilar and the reference product. Supporting data is collected through extensive analytical testing that sets the focus differently than for product development. A customized study design is required for each respective task. ZentriForce Pharma offers to design a suitable analytical portfolio and aid you on your way to release your biosimilar.

Please proceed to our biosimilarity page for further information.

Peptide Development

Peptides comprise a family of molecules that include fragments of proteins, hormones, toxins, antimicrobials, and many more. Their therapeutic value is high, but analytical handling of peptides is challenging, and instrumentation is run at its physical limits.  Expertise and extensive experience in working with small species such as peptide-based APIs is imperative for successful method development. Our scientists have worked with a large number of peptide-drugs. They will be valuable assets where expertise and consultation in analytical method development are concerned.  Please proceed to our peptide page for further information.

For biopharmaceutical development we focus on support of production optimization, the development of analytical methods, or assistance in formulation development. For further information please proceed to our biopharmaceutical development page.

Within biosimilarity studies it is on the collection of evidence that proves no differences (larger than method variability) in structure and purity exist between a proposed biosimilar and the reference product. Evidence is collected through extensive analytical testing. The difference in focus between development and biosimilarity testing requires a different mindset and a different study design for the respective task. ZentriForce Pharma can be a valuable partner on your way to release a biosimilar. For further information, please proceed to our biosimilarity page.

Despite being far less complex than full proteins, analytical handling of peptides is challenging.  Species as small as peptide-based APIs require analytical instrumentation to be run at its physical limits.  Expertise and extensive experience in working with such materials is imperative for successful method development. Our scientists have worked with a large number of peptide-based APIs, with sizes down to 1 kDa. They will be valuable assets where expertise and consultation in analytical method development are concerned.  For further information please proceed to our peptide page.

AUC is a first principle method. Therefore, the separation mechanism is well understood and extensively described. Please follow the link to a detailed description of AUC theory. 

ZentriForce Pharma offers a wide range of analytical techniques. Please follow the link to our analytical portfolio. 

Interested in Analytical Services ?

We are more than happy to assist you with your biosimilarity study.
Contact Us
ZentriForce Quality System
ZentriForce Pharma has established a laboratory quality system that closely follows the extensive and detailed guidelines provided by the WHO and the principle of “writing what you do and doing what you write”. ZentriForce implements procedural, equipment and analytical SOPs. To date, close to 30 SOPs are in place.
Click here for more information
Gene Therapy
For gene therapy product development, traditional quality attributes (e.g. purity) as well as new quality attributes (e.g. the ratio of particles that carry nucleic acids to empty particles) must be addressed. The diversity of approaches for gene therapy API analysis adds a further challenge to product characterization. Our scientists have worked with a wide range of different gene therapy products, ranging from small DNA / RNA complexes over lyposome-based carrier systems and adeno-associated viruses (AAV) to viruses that are several hundred nanometers in size.
Click here for more information
Biosimilarity
Within biosimilarity studies attention is on the collection of evidence that proves that no differences (larger than method variability) in structure and purity exist between a proposed biosimilar and the reference product. Evidence is collected through extensive analytical testing. The different focus between development and biosimilarity testing require an adjusted mindset and a customized study design for the respective task. ZentriForce Pharma can be a valuable partner on your way to release a biosimilar
Click here for more information
Peptides
Despite being far less complex than full proteins, analytical handling of peptides is challenging. Species as small as peptide-based APIs require analytical instrumentation to be run at its physical limits. Expertise and extensive experience in working with such materials is imperative for successful method development. Our scientists have worked with a large number of peptide-based APIs, with sizes down to 1 kDa. They will be valuable assets where expertise and consultation in analytical method development are concerned.
Click here for more information
Previous slide
Next slide
ZentriForce Quality System
ZentriForce Pharma has established a laboratory quality system that closely follows the extensive and detailed guidelines provided by the WHO and the principle of “writing what you do and doing what you write”. ZentriForce implements procedural, equipment and analytical SOPs. To date, close to 30 SOPs are in place.
Click here for more information
Gene Therapy
For gene therapy product development, traditional quality attributes as well as new quality attributes must be addressed. Our scientists have worked with a wide range of different gene therapy products, ranging from small DNA / RNA complexes over lyposome-based carrier systems and adeno-associated viruses (AAV) to viruses that are several hundred nanometers in size.
Click here for more information
Biosimilarity
Within biosimilarity studies attention is on the collection of evidence that proves that no differences (larger than method variability) in structure and purity exist between a proposed biosimilar and the reference product. Evidence is collected through extensive analytical testing.
Click here for more information
Peptides
Despite being far less complex than full proteins, analytical handling of peptides is challenging. Species as small as peptide-based APIs require analytical instrumentation to be run at its physical limits. Expertise and extensive experience in working with such materials is imperative for successful method development. Our scientists have worked with a large number of peptide-based APIs, with sizes down to 1 kDa.
Click here for more information
Previous slide
Next slide

Zentriforce Pharma Research GmbH 2019 – all rights reserved